company background image
EMMA logo

Emmaus Life Sciences OTCPK:EMMA Stock Report

Last Price

US$0.012

Market Cap

US$766.4k

7D

-7.7%

1Y

-88.3%

Updated

14 May, 2025

Data

Company Financials

Emmaus Life Sciences, Inc.

OTCPK:EMMA Stock Report

Market Cap: US$766.4k

EMMA Stock Overview

A commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. More details

EMMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Emmaus Life Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Emmaus Life Sciences
Historical stock prices
Current Share PriceUS$0.012
52 Week HighUS$0.11
52 Week LowUS$0.0001
Beta8.49
1 Month Change-22.58%
3 Month Change-70.00%
1 Year Change-88.35%
3 Year Change-97.00%
5 Year Change-99.12%
Change since IPO-99.88%

Recent News & Updates

Recent updates

Shareholder Returns

EMMAUS PharmaceuticalsUS Market
7D-7.7%-6.3%5.1%
1Y-88.3%-14.7%10.6%

Return vs Industry: EMMA underperformed the US Pharmaceuticals industry which returned -10% over the past year.

Return vs Market: EMMA underperformed the US Market which returned 11.5% over the past year.

Price Volatility

Is EMMA's price volatile compared to industry and market?
EMMA volatility
EMMA Average Weekly Movement38.6%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market4.2%

Stable Share Price: EMMA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: EMMA's weekly volatility has decreased from 275% to 39% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200035Willis Leewww.emmausmedical.com

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its pipeline products include ELS004, a pharmaceutical grade L-glutamine that is in Phase 1 clinical trial to treat diverticulosis.

Emmaus Life Sciences, Inc. Fundamentals Summary

How do Emmaus Life Sciences's earnings and revenue compare to its market cap?
EMMA fundamental statistics
Market capUS$766.39k
Earnings (TTM)-US$6.45m
Revenue (TTM)US$16.65m

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EMMA income statement (TTM)
RevenueUS$16.65m
Cost of RevenueUS$1.20m
Gross ProfitUS$15.45m
Other ExpensesUS$21.91m
Earnings-US$6.45m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.10
Gross Margin92.79%
Net Profit Margin-38.75%
Debt/Equity Ratio-52.6%

How did EMMA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/14 13:52
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Emmaus Life Sciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bradley SorensenZacks Small-Cap Research